Amgen, AstraZeneca plan 2015 brodalumab filings on third Phase III success
This article was originally published in Scrip
Executive Summary
Amgen plans to seek regulatory approvals for the psoriasis treatment brodalumab in 2015 now that the company and its partner AstraZeneca have reported success in a third Phase III clinical trial – the biologic's second late-stage victory over Johnson & Johnson's Stelara (ustekinumab).